Gonyautoxin II

DB19186InvestigationalSmall molecule

Gonyautoxin II is under investigation in clinical trial NCT04799041 (Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study).

Formula / weight: C₁₀H₁₇N₇O₈S · 395.35 g/mol (avg)
Also known as: 1h,10h-pyrrolo(1,2-c)purine-9,10,10-triol, 2,6-diamino-4-(((aminocarbonyl)oxy)methyl)-3a,4,8,9-tetrahydro-, 9-(hydrogen sulfate), (3as-(3a.alpha.,4.alpha.,9.beta.,10ar*))- 11.alpha.-hydroxysaxitoxin 11-sulfate · Gonyautoxin 2 · Gonyautoxin iim
Code names: GTX2 · GTX II

Resolves to

Compound

UNIIYU77Z3NY6ZCAS60508-89-6ChEBI80769KEGGC16856

Structure

InChIKeyARSXTTJGWGCRRR-XXKOCQOQSA-NSMILES[H][C@@]12NC(=N)N[C@]11N(C[C@@H](OS(O)(=O)=O)C1(O)O)C(=N)N[C@H]2COC(N)=O

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Gonyautoxin II, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account